Last reviewed · How we verify

Nycoton (CHLORAL HYDRATE)

discontinued Small molecule

Nycoton works by acting as a central nervous system depressant, slowing down brain activity to induce sleep or anesthesia.

Nycoton, also known as chloral hydrate, is a small molecule drug in the chloral hydrate class. It was originally developed by an unknown entity and its current owner is also unknown. Nycoton is used to treat general anesthesia and insomnia. The commercial status of Nycoton is unclear, but it is likely off-patent. Key safety considerations include its potential for dependence and abuse.

At a glance

Generic nameCHLORAL HYDRATE
Drug classchloral hydrate
ModalitySmall molecule
Therapeutic areaNeuroscience
Phasediscontinued

Mechanism of action

Imagine your brain is a busy city with lots of activity. Nycoton is like a traffic controller that slows down the flow of traffic, making it easier to fall asleep or relax. This is because it affects the way brain cells communicate with each other, leading to a decrease in activity and a sense of calm.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: